SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
bluelakes
dorightbythem
drtom1234
erippetoe
Smoke Reader
weatherproof
To: patlawche11 who wrote (47420)11/9/2018 2:04:05 PM
From: patlawche116 Recommendations  Read Replies (1) of 63283
 
Updated today to recruiting: Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer

Locations
United States, Connecticut
Smilow Cancer Hospital at Yale-New HavenRecruiting
New Haven, Connecticut, United States, 06510
Contact: Ebony Williams 203-785-5720 ebony.williams@yale.edu
Contact: Shelby DeCarlo 203-737-6299 shelby.decarlo@yale.edu
Principal Investigator: Daniel Petrylak, MD

United States, Nebraska
Urology Cancer CenterRecruiting
Omaha, Nebraska, United States, 68130
Contact: Stacy Moore 402-697-2229 smoore@gucancer.com
Principal Investigator: Luke Nordquist, MD

United States, New York
Weill Cornell MedicineRecruiting
New York, New York, United States, 10021
Contact: Pryianka Patel prp2013@med.cornell.edu
Contact: Monique Tarrant mot2013@med.cornell.edu
Principal Investigator: Scott T. Tagawa, MD, MS
clinicaltrials.gov
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News